p. 1−8
2357-0717
Vol.25/No.1
p. 9−15
2357-0717
Vol.25/No.1
p. 17−21
2357-0717
Vol.25/No.1
p. 22−30
2357-0717
Vol.25/No.1
p. 31−38
2357-0717
Vol.25/No.1
p. 39−44
2357-0717
Vol.25/No.1
70% ST segment resolution) Results: Post-PPCI LV GLS and LVEF were significantly higher in ICSK group (P = 0.005, 0.02 respectively). Post PPCI E/e' was significantly lower in ICSK group (P = 0.007). Peak CK-MB, CK-MB area under the curve (AUC), Troponin-I (72-hr); representing the enzymatic infarct size, were significantly lower in the ICSK group (P = 0.015, < 0.001, < 0.001 respectively). STR > 70% after PPCI was significantly higher in ICSK group (P = 0.045). Post-PPCI TFC was significantly lower in the ICSK group (P = 0.05). Post-PPCI MBG & TMPG were significantly higher in ICSK group (P = 0.04, 0.03 respectively). Multivariate linear regression analysis showed that each of ICSK administration, pain to stent time interval, post-PPCI MBG were independent predictors for LV GLS improvement after PPCI. Multivariate logistic regression analysis showed that the likelihood of achieving successful reperfusion post-PPCI was also associated with ICSK administration [OR= 0.123, 95% CI (0.02 - 0.75), P = 0.024] and was inversely associated with pain to stent time interval [OR= 0.995, 95% CI (0.990-0.999), P = 0.015]. Conclusion: Low-dose ICSK given immediately after primary PCI significantly led to improvement of LV GLS and LVEF, E/e'. It also reduced the enzymatic infarct size and was an independent predictor of successful reperfusion and LV GLS improvement after PPCI.]]>
p. 45−54
2357-0717
Vol.25/No.1
p. 55−63
2357-0717
Vol.25/No.1
p. 64−70
2357-0717
Vol.25/No.1
p. 71−78
2357-0717
Vol.25/No.1
p. 79−84
2357-0717
Vol.25/No.1
p. 85−91
2357-0717
Vol.25/No.1
1). ROC analysis revealed that methylated DNA can differentiate uncontrolled or partially controlled asthmatic patients and controlled asthmatic patients with AUC of 0.891 for DNA methylation. The optimal sensitivity and specificity were (86.1% and 89.3% at a cutoff expression value >2.2). Conclusion: our study suggested that increased methylation at the ADRB2 promoter area is associated with increased asthma susceptibility and poor asthma control which put it as a possible diagnostic and prognostic biomarker for asthma assessment in the near future.]]>
p. 92−100
2357-0717
Vol.25/No.1
p. 101−109
2357-0717
Vol.25/No.1
p. 110−115
2357-0717
Vol.25/No.1
p. 116−125
2357-0717
Vol.25/No.1
p. 126−131
2357-0717
Vol.25/No.1
p. 132−148
2357-0717
Vol.25/No.1
p. 149−154
2357-0717
Vol.25/No.1
p. 155−163
2357-0717
Vol.25/No.1
p. 164−170
2357-0717
Vol.25/No.1
p. 171−186
2357-0717
Vol.25/No.1